This design project explores the local values and mentality of the inhabitants of the French village Embres-et-Castelmaure, and the contrasting perspectives of the village by tourists, immigrants and temporary workers. There is an intriguing theoretical duality between fundamental and superficial cosmopolitanism, cosmopolitanism being described as an attitude/behaviour towards the use of the village. The fundamental attitude prioritzes interdependence between humans and nature, conviviality and collectivity (locals) whereas superficial cosmopolitanism views transform the village into a commodification. Currently, the village is consumed by tourists in an efficient and functional way, in the sense that tourists buy wine and then leave the village, granting instant gratification, However, this generalizes rural villages, flattening its local specificity and disregards its true spirit. My project thus focuses on the power of anticipation in contrast to instant gratification which we have become accustomed to in the 21st century. A collection of local observations (interviews, photography, sounds recordings) have informed the design decision to transform the old local church Chapelle de St. Felix and the old castle wall ruin Castelmaure to a local self-sufficient food laboratory and sleeping accommodation. The objective is to extend tourists's visits and give them a taste of the local living conditions and mentality, while stimulating the collective attitude among local inhabitants, and facilitating self-sufficiency, their dependency on seasonal produce and their collective love for food.

Background: The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. Methods: Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS). Results: A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8–2.3) and 5.4 months (95% CI, 4.0–6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0–1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS. Conclusions: Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2. Funding: Johannes J.M. Kwakman received an unrestricted research grant from Servier.

@en